Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 9 de 9
Filtrer
Plus de filtres








Gamme d'année
1.
Article de Chinois | WPRIM | ID: wpr-494353

RÉSUMÉ

Inflammatory bowel disease(IBD)is a kind of chronic and non-specific inflammatory disease comprising Crohn’s disease(CD)and ulcerative colitis(UC),the etiology has not yet been clarified. Endothelin-1(ET-1)is an active polypeptide composed of 21 amino acid residues,which can constrict blood vessels by activating voltage-dependent Ca2 + channels in vascular smooth muscle cells. Studies have shown that ET-1 plays an important role in the pathogenesis of IBD. This article reviewed the progress in study on ET-1 in the pathogenesis of IBD.

2.
Chinese Journal of Rheumatology ; (12): 156-159,后插1, 2015.
Article de Chinois | WPRIM | ID: wpr-603687

RÉSUMÉ

Objective To investigate autoantibody against endothelin receptor type A (ENRA-Ab) in patients with systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-PAH).The possibility of autoantibody-mediated pathogenesis in the development of SLE-PAH has also been explored.Methods ENRA-Ab in the serum of SLE-PAH and controls were detected by using a human ETRA epitope peptide-based ELISA.The clinical relevance of ENRA-Ab in SLE-PAH was analyzed.Proliferation of vascular smooth muscle cells (SMCs) and permeability of endothelial cells in vitro under the stimulation of polyclonal ENRA-Ab IgG were assessed.The expressions of PAH-related markers, i.e., 5-HTT, PDGFR-b, VEGF-A and PDGF-B were measured by qPCR.The effect of ENRA-Ab in vivo was also determined in a suboptimaldose monocrotaline-induced model with the assessment of right ventricle hypertrophy index and pathology parameters.Independent t-test, Tukey-Kramer test of variance analysis and Pearson' s correlation analysis were used for statistical analysis.Results ENRA-Abs was presented in a higher occurrence in SLE-PAH (35/85,41%) compared with controls (0/60;0, 13/80, 16%).There was a significant correlation between ENRA-Ab and echocardiograph estimated pulmonary arterial systolic pressure (r=0.392, P=0.002) in SLE-PAH.ENRA-Ab could promote SMCs proliferation, disrupt endothelial barrier and up-regulate PAH-related markers expression,which could be blocked in the presence of ETR antagonist.ENRA-Ab aggravated right ventricle hypertrophy and vascular remodeling in vivo.Conclusion ENRA-Ab is a new biomarker, in SLE-PAH, which may mediate PAH development in SLE.

3.
Chinese Journal of Geriatrics ; (12): 500-502, 2012.
Article de Chinois | WPRIM | ID: wpr-426574

RÉSUMÉ

Objective To observe the mRNA expressions of endothelin-1(ET-1) and endothelin A/B receptors (ETA/B) in tissue of benign prostatic hyperplasia treated by daily low-dose sildenafil.Methods A total of 32 patients with benign prostatic hyperplasia were randomly divided into two groups:treatment(25 mg sildenafi for 12 weeks,n=16) and control (no drug,n=16) groups.Immunohistochemical staining,ELISA and RT-PCR were used to detect the expression levels of ET-1 protein and ET A/B mRNA,respectively.Results The expressions of ET-1 protein and ET A/B mRNA in prostatic tissue were significantly lower in treatment group than in control group[(53.31±18.56) ng/kg vs.(83.34±31.38) ng/kg,0.356±0.056 vs.0.624±0.083,0.721±0.083 vs.0.933±0.905,t=-3.295,10.715,6.937,all P<0.001].Conclusions Daily low-dose sildenafil can reduce the expressions of ET-1 and ET A/B receptors mRNA in benign prostatic hyperplasia.

4.
Cancer Research and Clinic ; (6): 282-285, 2012.
Article de Chinois | WPRIM | ID: wpr-428774

RÉSUMÉ

Prostate cancer represents one of the most common cancer in men, and the treatment of castrate refractory prostate cancer (CRPC) is still a challenge in the clinical practice,as there are few effective therapies to lengthen patients life.Nowadays,with the expansion of knowledge regarding the biology of CRPC,many novel approaches which are currently in development yielded promising results in the clinical setting for patients.

5.
Article de Anglais | WPRIM | ID: wpr-211275

RÉSUMÉ

Endothelin (ET)-1 and its receptors (ETA and ETB receptor) are present in the central nervous system. ET exerts biological effects on gliogenesis and glial cell functions. In order to define a possible mechanism of ETA receptor signaling, the distribution of the ETA receptor in developing oligodendrocytes and the effects of ET-1 on the myelination of oligodendrocytes were examined. ETA receptor immunoreactivity was confined to the perivascular elements of the blood vessels during early postnatal development. However later in development, ETA receptor immunoreactivity was no longer observed in the vessels but became localized to the myelinating oligodendrocytes of the primitive corpus callosum of the white matter, apart from the vessels. ET-1 induced myelin basic protein (MBP) in primary oligodendrocyte precursor cell culture though the ETA receptor and was blocked by an ETA receptor antagonist. In addition, ET-1 evoked the release of Ca2+ which is a central regulator of oligodendrocyte differentiation. Our results provide a link between ET-1 and its ETA receptor and myelination during oligodendrocyte differentiation.


Sujet(s)
Animaux , Souris , Rats , Encéphale/anatomopathologie , Calcium/métabolisme , Signalisation calcique , Cellules cultivées , Endothéline-1/métabolisme , Souris de lignée ICR , Protéine basique de la myéline/génétique , Gaine de myéline/physiologie , Oligodendroglie/cytologie , Rat Sprague-Dawley , Récepteur de type A de l'endothéline/métabolisme
6.
Chinese Journal of Radiology ; (12): 580-583, 2011.
Article de Chinois | WPRIM | ID: wpr-416552

RÉSUMÉ

Objective To investigate whether the injured vascular endothelial plays an important role in the membranous formation of the inferior vena cava (IVC). Methods There were 40 cases of membranous obstruction of inferior vena cava (MOVC) in the experimental group and 40 arrhythmic inpatients in the control group from affiliated hospital .There were 23 males and 17 females in experimental group while 21 males and 19 females in control group, and the age were (41.8±8.1) yrs and (43.2±7.6) yrs respectively. All of them had no anti-coagulation (clotting) drug history and smoking history, no hypertension, no pulmonary artery hypertension, no coronary heart disease, no valvular disease, no myocardial disease, no blood disease, no diabetes, no connective tissue disease and malignancy, and liver and renal function must be normal. And then the serum concentrations of von Willebrand factor(vWF), endothelin-1(ET-1), vascular endothelial growth factor(VEGF) were defined by enzyme-linked immunosorbent assay (ELISA). The results were analyzed with independent sample t-test. Results In MOVC patients, the serum concentrations of vWF, ET-1 and VEGF[ (37.8±6.6) μg/L, (31.9±6.0) ng/L, (20.84±5.78) μg/L] were higher than those in the control group[ (3.3±1.3) μg/L, (5.3±1.8) ng/L, (4.2±1.2) μg/L. t=32.65,26.70,17.85,P<0.01, respectively]. ConclusionsThe injury of vascular endothelium is related to the formation of membrane in the IVC.

7.
Chinese Journal of Dermatology ; (12): 463-466, 2009.
Article de Chinois | WPRIM | ID: wpr-394058

RÉSUMÉ

Objective To investigate the effects ofendothelin-1 (ET-1) and endothelin-3 (ET-3) on the expression of transformation growth factor-beta 1 (TGF-β1) and phosphorylation of Smad 3 in malignant melanoma cell line, A375. Methods Cultured A375 cells were classified into 5 groups, i.e. control group (no stimulation), ET-1 group (stimulated with ET-1), ET-1+BQ123 group (treated with ET-1 and BQ123),ET-1 + BQ788 group (treated with ET-1 and BQ788), ET-3 group (stimulated with ET-3), to receive different stimulation. The working concentrations were 0, 0.1, 1, 10, 100 nmol/L for ET-1 and ET-3, 10 μmol/L for BQ123 and BQ788. After another 12- and 24-hour culture, ELISA, RT-PCR and Western blot were used to detect the expression of TGF-β1 protein and mRNA as well as phosphorylated Smad 3 (P-Smad 3). Results The expression of TGF-β1 in A375 cells was up-regulated by ET-1, but down-regulated by ET-3, and both of the effects were in a concentration-dependent manner. Under the stimulation with ET-1 and ET-3 of 100 nmol/L, the level of TGF-β1 reached 1289.38 ± 89.42 ng/L per 105 cells and 85.09 ± 9.37 ng/L per 105 cells, respectively, significantly different from that in unstimulated cells (both P < 0.05). BQ123 signifi-cantly blocked the up-regnlatory effect of ET-1 on the expression TGF-β1 protein(P < 0.05), but BQ788 had no significant influence on the effect, so was the case with TGF-β1 mRNA. Western blot revealed that ET-1significantly elevated the expression of P-Smad 3 in A375 cells (P <0.05), and the elevation was significantly inhibited by BQ123, but not by BQ788. The expression of P-Smad 3 was statistically decreased by ET-3 in A375 cells (P <0.05). Conclusions The expression of TGF-β1 could be enhanced by ET-1, but suppressed by ET-3. It is likely that endothelin receptor A mediates the phosphorylation of Smad 3 induced by ET-1.

8.
Article de Coréen | WPRIM | ID: wpr-158083

RÉSUMÉ

PURPOSE: In order to investigate the role of endothelins in the cardiac development, the present study was designed to examine the effects of endothelin A receptor(ETAR) antagonist to the cellular proliferation and apoptosis in the neonatal rat heart. In addition, the expression of various regulatory genes in protein and mRNA levels by ETAR antagonist were examined. METHODS: Neonatal Spargue-Dawley rats were separated into two groups. The BMS group(N=22) was treated with the selective ETAR antagonist(Bristo-Myers Squibb-182874; 300 mg/Kg/day) and the control group(N=20) with normal saline for seven days by orogastric tube. On the following day, their hearts were harvested for determination of apoptosis by modified TUNEL technique and cellular proliferation by PCNA stain. In addition to this, Western blottings and RT-PCRs of bcl-x, clusterin, p53 and TGF-beta1 were performed. RESULTS: The BMS group resulted in a reduced body weight, but not a significantly reduced heart weight. In the BMS group, cardiac apoptotic cells and PCNA positive cells were decreased(P<0.05). In the BMS group, clusterin and bcl-x protein expressions were increased(P<0.05), but p53 and TGF-beta1 protein expressions remained the same. In the BMS group, clusterin and TGF-beta1 mRNA expressions were increased(P<0.05), but bcl-x and p53 mRNA expressions remained the same. CONCLUSION: ETAR antagonist treatment decreases cell turnover in the developing rat heart, which may account for the role of endothelins on modulating cardiac growth. These changes may be affected by clusterin and bcl-x expressions. These results support that there are some roles of endothelin and ETAR in the cellular level of early neonatal cardiac growth.


Sujet(s)
Animaux , Rats , Apoptose , Protéine bcl-X , Technique de Western , Poids , Prolifération cellulaire , Clusterine , Endothélines , Gènes régulateurs , Coeur , Méthode TUNEL , Antigène nucléaire de prolifération cellulaire , Récepteur de type A de l'endothéline , ARN messager , Facteur de croissance transformant bêta , Facteur de croissance transformant bêta-1
9.
Article de Chinois | WPRIM | ID: wpr-563464

RÉSUMÉ

0.05). CO decreased at T2, T3, T4 and T5 compared with that at T0 in both groups (P

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE